Compare HRI & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRI | FOLD |
|---|---|---|
| Founded | 1965 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Corporate Leasing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.5B |
| IPO Year | 2006 | 2006 |
| Metric | HRI | FOLD |
|---|---|---|
| Price | $101.53 | $14.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $176.17 | $27.25 |
| AVG Volume (30 Days) | 544.8K | ★ 2.7M |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.97% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $4,376,000,000.00 | N/A |
| Revenue This Year | $10.35 | $20.50 |
| Revenue Next Year | $6.15 | $18.59 |
| P/E Ratio | $3,134.67 | ★ N/A |
| Revenue Growth | ★ 22.65 | N/A |
| 52 Week Low | $88.45 | $5.66 |
| 52 Week High | $188.35 | $14.47 |
| Indicator | HRI | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 40.98 | 73.15 |
| Support Level | N/A | $14.21 |
| Resistance Level | $130.75 | N/A |
| Average True Range (ATR) | 5.25 | 0.02 |
| MACD | 1.26 | -0.00 |
| Stochastic Oscillator | 63.97 | 90.91 |
Herc Holdings is an equipment rental company that was spun out of Hertz Global in 2016. It is currently the third-largest player in North America, after United Rentals and Sunbelt Rentals, with an approximate 6% market share pro forma for its 2025 acquisition of H&E Equipment Services. It serves a similar mix of companies to its peers (industrial, commercial, and residential construction) from its 450 locations targeting the top 100 metropolitan markets in the US. Herc's rental fleet of approximately $7 billion is also similar in composition to its peer group in terms of equipment offered. The company is also pursuing diversification by bundling and increasing specialty solutions for its customer base. Herc's portfolio skews toward local customers versus national accounts (60%/40%).
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.